Cite
HARVARD Citation
Phillips, R. et al. (2020). Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial. Lancet. 395 (10232), pp. 1259-1267. [Online].